Key result
Direct oral anticoagulants are a reasonable alternative to low-molecular-weight heparin for treating cancer-associated venous thromboembolism, offering comparable efficacy but increased bleeding risk.
Why the study?
Evidence for DOACs as alternatives to LMWH in cancer-associated venous thromboembolism has been inconclusive, with challenges arising from comorbidities and bleeding risks.
Do direct oral anticoagulants (DOACs) provide comparable efficacy and safety to low-molecular-weight heparin (LMWH) or vitamin K antagonists in patients with cancer-associated venous thromboembolism?
Do direct oral anticoagulants (DOACs) provide comparable efficacy and safety to low-molecular-weight heparin (LMWH) or vitamin K antagonists in patients with cancer-associated venous thromboembolism?
Answers are grounded in this paper and cite their sources.
DOACs offer a convenient alternative to LMWH for cancer-associated VTE with comparable efficacy, but require careful patient selection due to a higher risk of bleeding, particularly in those with gastrointestinal malignancies or renal impairment.
Cancer-associated venous thromboembolism (CAT) is a common complication associated with high morbidity and mortality. In accordance with major clinical trials comparing low-molecular-weight heparin (LMWH) with a vitamin K antagonist (VKA), LMWH is currently the standard treatment for CAT, owing to its efficacy for thrombosis recurrence and improved safety profile compared to VKA. Over the past few years, direct oral anticoagulants (DOACs) have emerged as potential alternative therapies to LMWH due to their convenient route of administration and predictable pharmacokinetics, but evidence for their use in CAT is inconclusive, as only a small fraction of the study populations in these trials had CAT. Recently, two large head-to-head trials comparing DOACs to LMWH in CAT patients reported comparable efficacies of DOACs with increased bleeding risk. Occasionally, CAT treatment can be challenging due to the heterogeneity of underlying malignancies and comorbidities. Renal insufficiency and gastrointestinal defects are the main obstacles in anticoagulant selection. Careful choice of treatment candidates and proper anticoagulant strategies are critical for the treatment of CAT; hence, more studies are required to address these challenges.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2019) conducted a review in Cancer-associated venous thromboembolism. Direct oral anticoagulants vs. Low-molecular-weight heparin was evaluated. Direct oral anticoagulants are a reasonable alternative to low-molecular-weight heparin for treating cancer-associated venous thromboembolism, offering comparable efficacy but increased bleeding risk.
Synapse has enriched 10 related papers. Consider them for comparative context: